Plant Name: Prangos pabularia
Taxonomic Information:
Plant ID: NPO19017
Plant Latin Name: Prangos pabularia
Taxonomy Genus: Prangos
Taxonomy Family: Apiaceae
Plant External Links:
NCBI TaxonomyDB:
52497
Plant-of-the-World-Online:
847470-1
Used in Medicines:
Country/Region:
China; IndiaTraditional Medicine System:
Indian Folk; TCM; Unani; AyurvedaMedicinal Functions:
Antipruritic; Aphrodisiac; Carminative; Diuretic; Emmenagogue; Oxytoxic; Stimulant; Stomachic
Geographical Distribution:
Afghanistan; Turkmenistan; Pakistan; Kazakhstan; India; Uzbekistan; China; Tajikistan
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| CNR1; CNR2; | |
| TSHR; | |
| FAAH; BLM; GLA; RECQL; ALDH1A1; POLB; | |
| TRPV1; | |
| NFKB1; | |
| SLCO1B3; SLCO1B1; | |
| NPC1; XPO1; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: | CYP2C19; |
|---|
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Enzyme_unclassified | FAAH | Anandamide amidohydrolase | O00519 | CHEMBL2243 |
| Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
| Enzyme_unclassified | GLA | Alpha-galactosidase A | P06280 | CHEMBL2524 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| SLC superfamily of solute carriers | SLCO1B3 | Solute carrier organic anion transporter family member 1B3 | Q9NPD5 | CHEMBL1743121 |
| SLC superfamily of solute carriers | SLCO1B1 | Solute carrier organic anion transporter family member 1B1 | Q9Y6L6 | CHEMBL1697668 |
| Small molecule receptor (family A GPCR) | CNR1 | Cannabinoid CB1 receptor | P21554 | CHEMBL218 |
| Small molecule receptor (family A GPCR) | CNR2 | Cannabinoid CB2 receptor | P34972 | CHEMBL253 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Transient receptor potential channel | TRPV1 | Vanilloid receptor | Q8NER1 | CHEMBL4794 |
| Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
| Unclassified | XPO1 | Exportin-1 | O14980 | CHEMBL5661 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0051001; negative regulation of nitric-oxide synthase activity | 1.629E-08 | 1.182E-04 | CNR1, CNR2, GLA |
| BP | GO:0050896; response to stimulus | GO:0042493; response to drug | 4.242E-08 | 2.309E-04 | BLM, CNR1, CNR2, NFKB1, NPC1, POLB, TRPV1, XPO1 |
| BP | GO:0050896; response to stimulus | GO:0010243; response to organonitrogen compound | 1.212E-06 | 3.769E-03 | BLM, CNR1, CNR2, NFKB1, NPC1, TRPV1, TSHR |
| MF | GO:0060089; molecular transducer activity | GO:0004949; cannabinoid receptor activity | 1.929E-06 | 4.909E-03 | CNR1, CNR2 |
| BP | GO:0009987; cellular process | GO:0038171; cannabinoid signaling pathway | 3.856E-06 | 8.396E-03 | CNR1, CNR2 |
| MF | GO:0003824; catalytic activity | GO:0009378; four-way junction helicase activity | 6.423E-06 | 1.166E-02 | BLM, RECQL |
| MF | GO:0003824; catalytic activity | GO:0043140; ATP-dependent 3'-5' DNA helicase activity | 1.348E-05 | 2.096E-02 | BLM, RECQL |
| MF | GO:0005488; binding | GO:0036310; annealing helicase activity | 1.796E-05 | 2.607E-02 | BLM, RECQL |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04080 | Neuroactive ligand-receptor interaction | 5.747E-05 | 4.425E-03 | CNR2, CNR1, TRPV1, TSHR |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05166 | HTLV-I infection | 1.049E-03 | 3.706E-02 | POLB, XPO1, NFKB1 |
| 09150 Organismal Systems | 09154 Digestive system | hsa04976 | Bile secretion | 1.444E-03 | 3.706E-02 | SLCO1B1, SLCO1B3 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04723 | Retrograde endocannabinoid signaling | 2.893E-03 | 5.570E-02 | FAAH, CNR1 |
| 09140 Cellular Processes | 09141 Transport and catabolism | hsa04142 | Lysosome | 4.255E-03 | 6.553E-02 | NPC1, GLA |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05164 | Influenza A | 8.428E-03 | 8.789E-02 | XPO1, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04024 | cAMP signaling pathway | 1.078E-02 | 8.789E-02 | NFKB1, TSHR |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05169 | Epstein-Barr virus infection | 1.110E-02 | 8.789E-02 | XPO1, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05203 | Viral carcinogenesis | 1.141E-02 | 8.789E-02 | POLB, NFKB1 |
| 09100 Metabolism | 09107 Glycan biosynthesis and metabolism | hsa00603 | Glycosphingolipid biosynthesis - globo series | 1.115E-02 | 8.789E-02 | GLA |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | CNR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Endocrine disease | E00-E35 | CNR1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | CNR2; |
| G00-G99: Diseases of the nervous system G00-G99 | Acute migraine | G43 | TRPV1; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pathological pain | R52, G89 | TRPV1; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Acute or chronic pain | R52, G89 | TRPV1; |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | CNR2; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR; |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | CNR1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | CNR1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CNR1; |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | CNR1; |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | CNR1; |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; CNR1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | CNR2; TRPV1; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | CNR2; |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | CNR1; |
| N00-N99: Diseases of the genitourinary system | Urinary incontinence | N39.3, N39.4, R32 | TRPV1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Lipid metabolism disorder | E75-E78 | CNR1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anorexia | F50.0-F50.1 | CNR1; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chemotherapy-induced nausea | R11 | CNR1; |
| NA: NA | Esophagus sensitivity | NA | TRPV1; |
| A00-B99: Certain infectious and parasitic diseases | Postherpetic neuralgia | B02.2, G44.847, G53.0 | CNR1; TRPV1; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | TRPV1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | CNR2; |
| C00-D49: Neoplasms | Overactive bladder disorder | C67, N32.81 | TRPV1; |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Immune disorder | D80-D89 | CNR2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | CNR1; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | CNR2; CNR1; TRPV1; |
| C00-D49: Neoplasms | Ovarian cancer | C56 | CNR1; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Musculoskeletal pain | R52, G89 | TRPV1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | CNR1; |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Nicotine dependence | F17 | CNR1; |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | CNR2; CNR1; TRPV1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | TRPV1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | CNR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | CNR1; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cough | R05 | TRPV1; |
| C00-D49: Neoplasms | Cancer | C00-C96 | NFKB1; |
| K00-K95: Diseases of the digestive system | Gastroesophageal reflux disease | K21 | TRPV1; |
>> Profiles of ingredients and activity landscape
>> Targets derived from weak experimental activities
